Shares of Novadaq Technologies Inc. (NASDAQ:NVDQ) (TSE:NDQ) have been assigned a consensus rating of “Hold” from the sixteen analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $12.00.

Several research firms have recently issued reports on NVDQ. Scotiabank reduced their target price on Novadaq Technologies from $15.50 to $13.25 and set an “outperform” rating on the stock in a report on Tuesday, June 20th. Canaccord Genuity lowered Novadaq Technologies from a “buy” rating to a “hold” rating and set a $11.75 target price on the stock. in a report on Monday, July 10th. Zacks Investment Research raised Novadaq Technologies from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Northland Securities reaffirmed a “hold” rating and issued a $11.75 price objective on shares of Novadaq Technologies in a research note on Monday, August 14th. Finally, Craig Hallum lowered Novadaq Technologies from a “buy” rating to a “hold” rating and set a $11.75 price objective on the stock. in a research note on Monday, June 19th.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/analysts-set-novadaq-technologies-inc-nvdq-price-target-at-12-00/1635190.html.

A number of institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its stake in Novadaq Technologies by 4.8% in the second quarter. JPMorgan Chase & Co. now owns 5,308,769 shares of the medical research company’s stock valued at $62,219,000 after acquiring an additional 243,261 shares during the period. FMR LLC grew its stake in Novadaq Technologies by 30.5% in the first quarter. FMR LLC now owns 3,107,271 shares of the medical research company’s stock valued at $24,206,000 after acquiring an additional 726,288 shares during the period. Janus Henderson Group PLC acquired a new stake in Novadaq Technologies in the second quarter valued at approximately $32,663,000. Clearbridge Investments LLC grew its stake in Novadaq Technologies by 0.4% in the first quarter. Clearbridge Investments LLC now owns 2,554,843 shares of the medical research company’s stock valued at $19,902,000 after acquiring an additional 9,371 shares during the period. Finally, Sand Grove Capital Management LLP purchased a new position in shares of Novadaq Technologies during the second quarter valued at approximately $27,072,000. 75.38% of the stock is owned by hedge funds and other institutional investors.

Novadaq Technologies (NASDAQ NVDQ) traded up inf% during midday trading on Wednesday, reaching $11.75. 395,280 shares of the company’s stock were exchanged. Novadaq Technologies has a 12 month low of $5.84 and a 12 month high of $12.74. The company’s market cap is $679.41 million. The company has a 50 day moving average price of $11.68 and a 200 day moving average price of $9.03.

About Novadaq Technologies

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Analyst Recommendations for Novadaq Technologies (NASDAQ:NVDQ)

Receive News & Ratings for Novadaq Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.